FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia The FDA-approved Vafseo tablets by Akebia Therapeutics for managing anemia in adult dialysis patients with chronic ...

It is without doubt one of the best plants to grow up a pergola. ‘Akebia produces delicate, fragrant flowers and attractive ...

Akebia Therapeutics has a one year low of $0.80 and a one year high of $2.48. The firm has a market capitalization of $414.54 million, a P/E ratio of -8.26 and a beta of 0.74.

Akebia to Host Conference Call on March 13, 2025, at 8:00 a.m. ETCAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release ...

Akebia has said it is prepping for a U.S. commercial launch of vadadustat in the second half if it gets an FDA green light. Akebia down 7% to $2.06. Akebia Therapeutics Inc.

CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended ...

The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GSK’s Jesduvroq.

Shares of AKBA stock opened at $1.86 on Thursday. Akebia Therapeutics has a twelve month low of $0.80 and a twelve month high of $2.48. The firm has a 50-day moving average price of $2.02 and a ...